Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Parsaclisib · INCB-050465

Small molecule · Inhibitor of phosphoinositide-3 kinase delta (PIK3CD) · developed by Incyte

Phase 1/2 Most advanced trial
INCY Developer
1 Registered trials

What is Parsaclisib?

Parsaclisib is a small molecule that inhibits the delta isoform of phosphoinositide-3 kinase (PI3K), preventing activation of the PI3K/AKT signaling pathway. It is being studied in non-Hodgkin lymphoma and diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INCB-050465
Drug type
Small molecule
Targets
phosphoinositide-3 kinase delta (PIK3CD)
Mechanism
Inhibitor of phosphoinositide-3 kinase delta (PIK3CD)
Pathways
PI3K/AKT signaling
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
OS7097575K

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04661007 Phase 1/2 Non Hodgkins Lymphoma Active not recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Large B-cell LymphomaNon Hodgkins Lymphoma

Other drugs acting on PIK3CD

More from Incyte

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Parsaclisib

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.